44th week of 2011 patent applcation highlights part 35 |
Patent application number | Title | Published |
20110268635 | SCR on Low Thermal Mass Filter Substrates - Provided are selective catalytic reduction (SCR) filters that effectively provide simultaneous treatment of particulate matter and NO | 2011-11-03 |
20110268636 | Carbon Dioxide Permeable Membrane - A carbon dioxide permeable membrane is described. In some embodiments, the membrane includes a body having a first side and an opposite second side; a plurality of first regions formed from a molten carbonate having a temperature of about 400 degrees Celsius to about 1200 degrees Celsius, the plurality of first regions forming a portion of the body and the plurality of first regions extending from the first side of the body to the second side of the body; a plurality of second regions formed from an oxygen conductive solid oxide, the plurality of second regions combining with the plurality of first regions to form the body and the plurality of second regions extending from the first side of the body to the second side of the body; and the body is configured to allow carbon dioxide to pass from the first side to the second side. | 2011-11-03 |
20110268637 | AIR POLLUTION CONTROL SYSTEM AND AIR POLLUTION CONTROL METHOD - An air pollution control system | 2011-11-03 |
20110268638 | METHOD OF MERCURY REMOVAL FROM COMBUSTION EXHAUST GAS AND COMBUSTION EXHAUST GAS PURIFICATION APPARATUS - A method for removing mercury in a combustion exhaust gas includes injecting ammonia or urea as a reducing agent into a combustion exhaust gas containing nitrogen oxides, sulfur dioxide, metallic mercury, and hydrogen halides, and then introducing the combustion exhaust gas to a denitration apparatus filled with a denitration catalyst to cause a denitration reaction and oxidize the metallic mercury to produce mercury halide; and introducing the combustion exhaust gas through an air preheater and an electric dust collector to a wet desulfurization apparatus, thereby removing sulfur dioxides and the mercury halide, wherein the ammonia concentration of the combustion exhaust gas at an exit of the denitration apparatus is maintained at 5 ppm or higher, and the mercury halide is adsorbed or precipitated onto combustion ash and collected by the electric dust collector to discharge the mercury halide out of a system. | 2011-11-03 |
20110268639 | METHOD AND A DEVICE FOR VERIFYING AND CONTROLLING THE REMOVAL OF HYDROGEN FLUORIDE FROM A PROCESS GAS - A gas cleaning system ( | 2011-11-03 |
20110268640 | PROCESS FOR THE PREPARATION OF MAGADIITE OR KENYAITE FROM AN ORGANIC STRUCTURING AGENT COMPRISING TWO TERMINAL ALCOHOL FUNCTIONS - Described is a process for the preparation of a crystallised lamellar solid formed by magadiite consisting of implementing in a step (i) mixing of at least one silica source, at least one salt of N,N,N′,N′-tetramethyl-N,N′-dibenzyloctanediammonium, at least one alkali and/or alkaline earth metal M and water and then implementing in a step (ii) hydrothermal treatment of said mixture until said crystallised lamellar solid constituted by magadiite is formed. | 2011-11-03 |
20110268641 | Process For Recovery Of High Boiling Waste - Waste streams from different chloromonosilane production processes are combined and reacted in a single recovery process. Useful monosilane species may be obtained with a single recovery process. | 2011-11-03 |
20110268642 | PROCESS FOR PURIFYING LOW MOLECULAR WEIGHT HYDRIDOSILANES - The present invention relates to a process for purifying low molecular weight hydridosilane solutions, in which a solution to be purified comprising a) at least one low molecular weight hydridosilane, b) at least one solvent and c) at least one impurity selected from the group of the compounds having at least 20 silicon atoms and/or the group of the homogeneous catalyst systems is subjected to a crossflow membrane process with at least one membrane separation step using a permeation membrane. | 2011-11-03 |
20110268643 | Production of Silicon - A process is provided for the production of elemental silicon from a silica containing glass melt including contacting the glass with a metal capable of undergoing a bimolecular reaction between the glass and metal at elevated temperature to reduce the oxidation state of the silicon in the glass to elemental silicon while oxidizing the metal, collecting, and optionally separating the elemental silicon. Similarly, elemental germanium is produced from a germania-containing glass. | 2011-11-03 |
20110268644 | PELLETIZED AMMONIUM SULFATE PARTICLES - The invention relates to a method for preparing pelletized ammonium sulfate particles, the method comprising—providing ammonium sulfate crystals;—isolating a fraction comprising crystals having an intermediate size from crystals having a small size and from crystals having a large size, thereby obtaining remaining crystals comprised of crystals having small size and crystals having large size; and—pelletizing through a die at least part of the remaining crystals, i.e. at least part of the crystals from which the fraction comprising crystals having the intermediate size have been isolated, thereby forming pelletized ammonium sulfate particles. | 2011-11-03 |
20110268645 | PROCESS FOR PRODUCING NITRIDE CRYSTAL, NITRIDE CRYSTAL AND APPARATUS FOR PRODUCING SAME - To grow a highly pure nitride crystal having a low oxygen concentration efficiently by an ammonothermal method. | 2011-11-03 |
20110268646 | PREPARATION METHOD OF CARBON NANOTUBE BY DECOMPOSING THE POLYMER WITH HYDROTALCITE AS A CATALYST - The present invention discloses a preparation method of carbon nanotube by decomposing the polymer with hydrotalcite as a catalyst, which belongs to the field of preparation technology of carbon nanotube (CNT). The technical solution of the present invention are as below: firstly, the hydrotalcite with the particle size at nanometer or sub-micron level is prepared, and then is added into the polymer. After the calcination process at high temperature and a treatment with acid, the nano-scale CNT can be obtained. The CNTs prepared by the method supplied in this invention not only have the advantages including high yield, uniform diameter, few structural defects, low impurity content, low cost and simple preparation process, which is suitable for large-scale industrial production, but also can solve the problem of recirculation of waste plastics and utilization of the resource. | 2011-11-03 |
20110268647 | PRODUCING TWO-DIMENSIONAL SANDWICH NANOMATERIALS BASED ON GRAPHENE - Two-dimensional nanomaterials are produced in a process comprising the steps of
| 2011-11-03 |
20110268648 | PROCESS AND SYSTEM FOR PRODUCTION OF DICHLORINE - The present disclosure provides a process and a system for producing dichlorine (Cl | 2011-11-03 |
20110268649 | CATALYST COMPRISING RUTHENIUM AND NICKEL FOR THE OXIDATION OF HYDROGEN CHLORIDE - Catalyst for gas-phase reactions which has a high mechanical stability and comprises one or more active metals on a support comprising aluminum oxide as support material, wherein the aluminum oxide component of the support consists essentially of alpha-aluminum oxide. | 2011-11-03 |
20110268650 | METHODS AND APPARATUS FOR SULFUR RECOVERY FROM ACID GASES - Apparatus and methods for recovering sulfur from acid gases. Acid gases containing relatively high amounts of carbonyl sulfide and/or one or more types of mercaptans can be treated in a sulfur recovery system employing an acid gas enrichment zone and a tail gas treatment zone, where partially-loaded sulfur absorbing solvent from the tail gas treatment zone is employed for sulfur absorption in the acid gas enrichment zone. Off-gas from the acid gas enrichment zone can be combined and hydrogenated with a sulfur recovery unit tail gas thereby increasing the total amount of sulfur recovery from the initial acid gas. | 2011-11-03 |
20110268651 | METHOD AND APPARATUS FOR STORING AND DELIVERING HYDROGEN - An apparatus and method for storing and releasing hydrogen is disclosed. In one embodiment, the apparatus includes a reactor, a heater having a first portion that is located in the reactor; a dehydrogenation catalyst that is affixed to the first portion of the heater; a hydrogen release conduit in communication with the reactor; a chamber containing a hydrogenated carrier; and an energy source coupled to the heater. | 2011-11-03 |
20110268652 | METHOD FOR THE INTEGRATED PRODUCTION OF CELLULOSE AND LOW-MOLECULAR-WEIGHT REUSABLE MATERIALS - The present invention relates to an integrated method for producing cellulose and at least one low-molecular-weight reusable material, in which a starting material containing lignocellulose is provided and subjected to a decomposition with a processing medium. A fraction enriched with cellulose and a fraction depleted of cellulose is then isolated from the decomposition material, the depleted fraction of cellulose being subjected to a treatment during which at least one low-molecular-weight reusable material is obtained. | 2011-11-03 |
20110268653 | Compositions and Methods Related to Acid Stable Lipid Nanospheres - The present invention relates generally to the fields of chemistry and biochemistry. More particularly, it concerns methods and compositions for the use of fatty asparagine, fatty cysteine, and fatty serine derivatives. | 2011-11-03 |
20110268654 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET - The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target. | 2011-11-03 |
20110268655 | ANTI-ALPHA V IMMUNOLIPOSOME COMPOSITIONS, METHODS AND USES - An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent. | 2011-11-03 |
20110268656 | J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE - In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided. | 2011-11-03 |
20110268657 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2011-11-03 |
20110268658 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 2011-11-03 |
20110268659 | HIGH SHEAR APPLICATION IN DRUG DELIVERY - In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises ( | 2011-11-03 |
20110268660 | METHOD FOR DETECTING DYSPLASIA - The present invention provides a method of imaging useful in the determination of sites of dysplasia in patients suffering from Barrett's oesophagus. The method comprises the use of an optical imaging agent comprising a vector which targets the extracellular domain of EGFR, the vector also being selective for EGFR over Her2. The vector is labelled with an optical reporter suitable for in vivo imaging using light in the green to near-infrared wavelength 500-1200 nm. Also provided are novel optical imaging agents suitable for use in the method. | 2011-11-03 |
20110268661 | FLUORESCENT FUSION POLYPEPTIDES AND METHODS OF USE - Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus. | 2011-11-03 |
20110268662 | FUNCTIONALIZED NANOCERIA COMPOSITION FOR OPHTHALMIC TREATMENT - The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma. | 2011-11-03 |
20110268663 | INTRAVASCULAR CONTRAST AGENTS - Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C | 2011-11-03 |
20110268664 | COMPOSITION FOR ADDITION TO DRINKING WATER - The invention relates to an effervescent composition for adding to the drinking water of an animal. The composition comprises an effervescent agent and a palatant. The composition may be used in hydration treatment of an animal, as an additive for animal drinking water and for delivering a micronutrient or functional ingredient. Animals are encouraged to drink more drinking water by the effervescent composition. | 2011-11-03 |
20110268665 | OIL-BASED FOAMABLE CARRIERS AND FORMULATIONS - A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described. | 2011-11-03 |
20110268666 | NOVEL GASTRORETENTIVE DELIVERY SYSTEM - A novel gastroretentive delivery system comprising a tablet comprising a pharmaceutical ingredient or diagnostic, which tablet comprises a gas releasing ingredient or a tandem of two gas releasing ingredients, an ingredient capable of unrestricted swelling in gastric fluid, an ingredient capable of limiting the unrestricted swelling and a hardening ingredient. The said system is based on the use of three different gastroretentive mechanisms: flotation, swelling and mechanical strength, the three mechanisms acting in a complimentary way. Processes for manufacturing same and methods of treatment are also disclosed. | 2011-11-03 |
20110268667 | Freshening Compositions Having A Malodor Control Component And Methods Thereof - A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor control component may include an effective amount of volatile aldehydes and/or an acid catalyst. | 2011-11-03 |
20110268668 | PROCESS FOR NEBULIZING AQUEOUS COMPOSITIONS CONTAINING HIGHLY CONCENTRATED INSULIN - A process for nebulizing highly concentrated solutions of insulin for administration by inhalation. | 2011-11-03 |
20110268669 | COMPOSITION AND METHOD FOR TREATING EUSTACHIAN TUBE DYSFUNCTION - A method of treating Eustachian tube dysfunction in a person includes placing the person's body in a position substantially lying on one of the person's left or right sides. The side on which the person is lying is the side affected by Eustachian tube dysfunction. A composition of simethicone in a concentration of about 0.05% to 0.65% wt/vol diluted in an aqueous carrier is introduced through the nasal cavity of the same side on which the person is lying. The simethicone composition is then allowed to coat the person's pharynx on the side of which the person is lying. | 2011-11-03 |
20110268670 | SYNTHETIC PEPTIDE CONSTRUCTS FOR THE DIAGNOSIS AND TREATMENT OF PERIODONTITIS ASSOCIATED WITH PORPHYROMONAS GINGIVALIS - The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium | 2011-11-03 |
20110268671 | Method of Maintaining Oral Health in Animals - Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a diseased caused by oral bacterial in an animal Formula (I); wherein R | 2011-11-03 |
20110268672 | Ferrate(VI)-Containing Compositions and Methods of Using Ferrate(VI) - Compositions containing ferrate(VI) are disclosed. Also, methods are disclosed that utilize ferrate(VI). | 2011-11-03 |
20110268673 | Skin Treatment - The present invention provides a method for determining the predisposition of an individual to a skin condition comprising identifying the profilaggrin alleles present in the genome of an ex vivo sample taken from the individual. Skin conditions include the ability of an individual to produce Natural Moisturising Factors (NMF), dry skin and/or predisposition to detergent-induced erythema. Typically profilaggrin alleles are identified by determining the number of encoded filaggrin repeats. Methods of the invention are particularly useful for grouping individuals for the purposes of participation in clinical trials or for matching an individual to a cosmetic preparation. | 2011-11-03 |
20110268674 | POLYAMIDE-5 COMPOUNDS IN COSMETIC PREPARATIONS - Polyamide-5 compounds show an increase of the care and/or efficacy properties of cosmetic or dermatological preparations, such as waterproofness, long-term stability, skin moisture and stickiness. The preparations preferably comprise one or more care agents or active ingredients selected from the group of UV filter substances, anti-wrinkle active ingredients, skin moisturizers and/or lipids. | 2011-11-03 |
20110268675 | Cosmetic Composition Using Low Molecular Weight Dimethicone - Cosmetic compositions which include low molecular weight non-volatile oils, such as dimethicone, along with silica and a volatile solvent are provided. Such compositions exhibit surprisingly beneficial properties such as long wear, resistance to color transfer, low tack and excellent comfort and shine. | 2011-11-03 |
20110268676 | Preservatives for Cosmetic, Toiletry and Pharmaceutical Compositions - A composition for and methods of preserving a topical cosmetic, toiletry or pharmaceutical formulation against microbiological contamination or growth are described in which the compositions used herein include at least one hydroxamic acid, salt or complex thereof, and the methods include addition of an effective amount of such compounds to a cosmetic, toiletry or pharmaceutical formulation. Compositions further including alkanediols and/or solubilizing agents in blends with hydroxamic acid are also described. | 2011-11-03 |
20110268677 | Silicone Paste Compositions - Silicone paste compositions are disclosed by combining a silicone organic elastomer gel with water or a hydrophilic solvent. The silicone paste compositions may further contain a personal or healthcare active. The silicone organic elastomer gel is prepared by reacting in a carrier fluid an organohydrogensiloxane with two polyoxyalkylenes, the first polyoxyalkylene having aliphatic unsaturation at both each molecular termini, and the second polyoxyalkylene having aliphatic unsaturation at one molecular terminal. | 2011-11-03 |
20110268678 | VITAMIN D FORMING SUNSCREEN - A composition suitable for providing protection against ultraviolet radiation containing one or more active ultraviolet radiation absorber through which ultraviolet radiation in approximately the 295 to 315 nanometer range is permitted to enter the skin in an amount sufficient for the body to produce a healthful and disease-opposing quantity of vitamin D | 2011-11-03 |
20110268679 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS - Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives. | 2011-11-03 |
20110268680 | HEAT STABLE PROTEIN INGREDIENTS - The subject invention pertains to methods of making crosslinked protein-carbohydrate conjugates (CPCCs) and uncrosslinked protein-carbohydrate conjugates (PCCs) that are heat, pH and salt stable. Methods of stabilizing CPCCs and PCCs are also provided. The PCCs and CPCCs formed according to the methods disclosed herein are useful in the food industry and for loading with substances of interest. | 2011-11-03 |
20110268681 | METHOD OF TREATING HAIR - There is provided herein a method of treating thermally and/or chemically damaged including the following steps:
| 2011-11-03 |
20110268682 | WAVING COMPOSITIONS - Disclosed are waving compositions for waving of keratinous fibers, such as hair, containing a) a bisulfite compound, b) a sulfate compound or urea, and c) a lactone or about 0.3% or greater, by weight, of ascorbic acid or a derivative thereof, based on the total weight of the composition and methods of waving keratinous fibers by applying such compositions to keratinous fibers. Also disclosed is a multi-unit cosmetic kit for treating a keratinous fiber containing a) a first unit containing a first composition containing a bisulfite compound and a sulfate compound or urea, and b) a second unit containing a second composition containing a lactone or ascorbic acid or a derivative thereof. | 2011-11-03 |
20110268683 | STRUCTURED SUSPENDING SYSTEMS - A pourable ringing gel surfactant composition comprising a mixture of at least one anionic surfactant having a C | 2011-11-03 |
20110268684 | HAIR CONDITIONERS COMPRISING IMIDAZOLINES AND ESTER OILS - Cosmetic preparations, in particular hair conditioners, contain at least one imidazoline derivative including at least two long fat groups, and at least two ester oils. | 2011-11-03 |
20110268685 | COSMETIC OR PERSONAL CARE COMPOSITION COMPRISING A POLYMER COMPRISING OXAZOLIDON GROUPS - The invention relates to a cosmetic or personal care composition comprising a polymer which polymer comprises oxazolidon groups. Examples of cosmetic and personal care compositions include hair spray compositions, mousses, gels, lotions, tonics, shampoos, conditioners, rinses, hand and body lotions, facial moisturizers, sunscreens, anti-acne preparations, topical analgesics, mascara's, eyeliners, blush, liquid lip color, nail polish foundations. | 2011-11-03 |
20110268686 | COSMETIC COMPOSITION INCLUDING AN ACANTHUS EXTRACT, AND USE OF ACANTHUS IN A COSMETIC HAIR-CARE COMPOSITION - The present invention relates to a new advantageous utilisation of acanthus in the cosmetic field, and more especially in a haircare composition for creating and/or maintaining the curling effect. | 2011-11-03 |
20110268688 | METHOD AND COMPOSITIONS FOR IMPROVING SKIN AND BODY APPEARANCE - A topical composition comprising at least one adipogenesis inhibitor and at least one adipocyte lipolytic agent and, optionally, at least one skin tightening agent; a method for improving the appearance of facial or body skin, treating the appearance of cellulite, or treating the face or body to improve the appearance of skin and uneven skin surfaces. | 2011-11-03 |
20110268689 | PHOTO-CROSSLINKABLE ANTIFOULING COMPOSITIONS, FILMS OBTAINED FROM SAID COMPOSITIONS, AND CORRESPONDING USES - Photo-crosslinkable antifouling compositions, in particular antibacterial, antifungal and anti-algae ones, which include the combination of at least one telechelic oligoisoprene of a particular formula with an agent for crosslinking the oligoisoprene. The antifouling film is obtained by applying a thin layer of such a liquid composition on a substrate and is crosslinked at room temperature by exposure to visible and/or UV radiations. The film can be used for preventing the occurrence of a biofilm on any surface in a humid or aqueous environment, and can be used as an additive for preparing materials with a view to imparting bacteriostatic and/or bactericidal properties thereto. | 2011-11-03 |
20110268690 | POLYMERS CONTAINING POLY(HYDROXYALKANOATES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME - Compositions comprising poly(hydroxyalkanoates) and agents for use with medical articles are described. | 2011-11-03 |
20110268691 | dsRNA Delivery Composition and Methods of Use - The present invention provides for compositions comprising a cucurbitacin bait for stimulating insect feeding and a dsRNA—such as for eliciting RNAi mediated gene silencing in an insect. The present invention also provides for methods of delivering a dsRNA molecule to an insect, inhibiting protein expression in an insect, and killing an insect by providing a dsRNA molecule. | 2011-11-03 |
20110268692 | Synergistic rodenticidal compositions - The present invention relates to the combination of an active anticoagulant rodenticidal compound with an analogue of vitamin D, with at least one of the two components being used at a very low concentration. | 2011-11-03 |
20110268693 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. | 2011-11-03 |
20110268694 | METHODS FOR TREATING VASCULAR LEAK SYNDROME - Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage. | 2011-11-03 |
20110268695 | USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS - Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade. | 2011-11-03 |
20110268696 | PREVENTION AND/OR TREATMENT OF MULTIPLE ORGAN DYSFUNCTION SYNDROME WITH INTERLEUKIN-22 - The present invention relates to use an agent for the prevention and/or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases. | 2011-11-03 |
20110268697 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2011-11-03 |
20110268698 | METHODS FOR TREATING HEPATITIS C - The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IBES activity. | 2011-11-03 |
20110268699 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES - Methods and pharmaceutical compositions for treating multiple sclerosis are described. The methods and pharmaceutical compositions include a therapeutically effective amount of one or more tetracyclic pyrazinoindoles, and/or pharmaceutically acceptable salts thereof. | 2011-11-03 |
20110268700 | DOSAGE REGIMENS FOR HCV COMBINATION THERAPY - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient. | 2011-11-03 |
20110268701 | STRESS-RESPONSIVE INDUCTION OF A THERAPEUTIC AGENT AND METHODS OF USE - This invention relates to compositions and methods for selective expression of a heterologous nucleic acid sequence in a targeted tissue, and more particularly to the glucose regulated protein 78 (grp78) stress-responsive promoter and its use in gene therapy and the production of transgenic animals. | 2011-11-03 |
20110268702 | LACTOBACILLUS PARACASEI AND WEIGHT CONTROL - The present invention generally relates to the field of obesity and/or metabolic disorders. In particular the present invention relates to the use of probiotics to treat obesity and/or metabolic disorders. One embodiment of the present invention relates to the use of | 2011-11-03 |
20110268703 | PROBIOTIC STRAIN AND ANTIMICROBIAL PEPTIDE DERIVED THEREFROM - A strain of | 2011-11-03 |
20110268704 | ENHANCED SHELF LIFE AND ON SEED STABILIZATION OF LIQUID BACTERIUM INOCULANTS - The present invention includes a method for producing a liquid inoculant containing a desiccant. The method can improve survival and stability of bacteria in liquid inoculants in pack and on seeds. The method includes providing a liquid inoculant of a bacteria grown to a substantially stationary phase. A desiccant treatment containing a desiccant is added to the liquid inoculant to form a partially desiccated inoculant product. The partially desiccated inoculant product can be packaged and stored. The partially desiccated inoculant product can also be applied to seeds. | 2011-11-03 |
20110268705 | HDAC4, HDAC5, HDAC6, HDAC7, AND HIF1 ALPHA MODULATION OF RETINAL CELL SURVIVAL - Methods for inhibiting retinal cell death by altering expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1α in a retinal cell are provided. | 2011-11-03 |
20110268706 | PREPARATION METHOD OF POROUS HYALURONIC ACID SPONGE FOR CELL DELIVERY SYSTEM - Provided is a preparation method of a porous hyaluronic acid sponge comprising the steps of: dissolving hyaluronic acid in an aqueous sodium hydroxide solution; adding an epoxy-based crosslinking agent to the resultant aqueous sodium hydroxide solution in which hyaluronic acid is dissolved and homogenizing the hyaluronic acid solution; hydrogelating the homogenized hyaluronic acid solution; washing the hydrogelated hyaluronic acid hydrogel with ultrapure water; swelling the washed hyaluronic acid hydrogel to attain porosity; and freeze-drying the hyaluronic acid hydrogel to obtain a porous hyaluronic acid sponge. | 2011-11-03 |
20110268707 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ. | 2011-11-03 |
20110268708 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. | 2011-11-03 |
20110268709 | Generation of Histocompatible Tissues Using Nuclear Transplantation - Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy. | 2011-11-03 |
20110268710 | METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS - A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats. | 2011-11-03 |
20110268711 | PANCREATIC STELLATE CELL SPECIFIC PROMOTER AND USES THEREOF - There is presently provided a method for effecting pancreatic stellate cell-specific gene expression comprising delivering a nucleic acid comprising a glial fibrillary acidic protein promoter operably linked to a coding sequence to a pancreatic stellate cell. | 2011-11-03 |
20110268712 | Stem Cells Suitable for Transplantation, Their Preparation and Pharmaceutical Compositions Comprising Them - The present invention relates to stem cells suitable for transplantation and to methods for their preparation. | 2011-11-03 |
20110268713 | Variants of Ancestral Uricases and Uses Thereof - The present invention provides uricases and methods of their production and use in reducing the amount of uric acid in a subject. The present invention further provides methods employing a uricase of this invention in the treatment and/or prevention of hyperuricemia, gout, tumor lysis syndrome and/or hypertension in a subject. | 2011-11-03 |
20110268714 | CD34 Stem Cell-Related Methods and Compositions - This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 | 2011-11-03 |
20110268715 | ANTI-INFLAMMATORY AND ANTI-VAGINITIS FOOD COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING LACTOBACILLUS - An anti-inflammatory and anti-vaginitis food composition and/or pharmaceutical composition includes | 2011-11-03 |
20110268716 | METHODS FOR THE ENRICHMENT OF VIABLE FOXP3+ CELLS AND USES THEREOF - The present invention is directed to methods of identifying and enriching for viable Foxp3 | 2011-11-03 |
20110268717 | Herbal-Based Compositions for Alleviating Symptoms Associated with Autism - Aspects of the invention relate to compositions comprising passiflora extracts that may improve neurological and behavioral symptoms associated with Pervasive Developmental Disorders. | 2011-11-03 |
20110268718 | CACTUS FRUIT EXTRACT - A method for producing a cactus fruit extract for use in formulating a beverage which can be used in the treatment of veisalgia. | 2011-11-03 |
20110268719 | Annatto Extract Compositions, Including Geranyl Geraniols And Methods Of Use - Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required. | 2011-11-03 |
20110268720 | FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF - The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine. | 2011-11-03 |
20110268721 | Therapy Regimens, Dosing Regimens And Stable Medicaments For The Treatment Of Pompe Disease - The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation. | 2011-11-03 |
20110268722 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS - Described are mitochondria-targeted anti-tumor agents, death receptor agonists, autophagy inhibitors, and NF-κB signaling pathway inhibitors, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation. | 2011-11-03 |
20110268723 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis. | 2011-11-03 |
20110268724 | METHODS AND MATERIALS RELATING TO CD84-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides. | 2011-11-03 |
20110268725 | Anti-NGF antibodies for the treatment of various disorders - The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorder in a patient without having a significant adverse effect on the immune system of the patient. | 2011-11-03 |
20110268726 | Anti-CD38 human antibodies and uses thereof - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore | 2011-11-03 |
20110268727 | ANTI-INTERFERON-ALPHA ANTIBODIES - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 2011-11-03 |
20110268728 | SOLUBILITY OPTIMIZATION OF IMMUNOBINDERS - The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention. | 2011-11-03 |
20110268729 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS BY NOGO-A-ANTAGONIST - The invention relates to methods for the treatment or prophylaxis of amyotrophic lateral sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a Nogo-A antagonist. | 2011-11-03 |
20110268730 | METHOD FOR INHIBITING BONE RESORPTION - The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated. | 2011-11-03 |
20110268731 | METHODS OF TREATING AUTOIMMUNE DISORDERS AND/OR INFLAMMATORY DISORDERS - The present invention relates to dendrimer compositions configured for treating inflammatory disorders and autoimmune disorders, and related methods of synthesis. Specifically, the present invention relates to methods for treating rheumatoid arthritis with PAMAM dendrimers having functional ligands configured for treating rheumatoid arthritis (e.g., therapeutic agents, pro-drugs, targeting agents, trigger agents, imaging agents) (e.g., methotrexate). | 2011-11-03 |
20110268732 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF - The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death. | 2011-11-03 |
20110268733 | ANTI-Siglec-15 ANTIBODY - Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like. | 2011-11-03 |
20110268734 | PREVENTIVE OR THERAPEUTIC AGENT FOR PSORIATIC ARTHRITIS COMPRISING IL-6 ANTAGONIST AS ACTIVE INGREDIENT - A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor. | 2011-11-03 |
20110268735 | MULTIMERIC CONSTRUCTS - Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors. | 2011-11-03 |